TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05854004

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Therapeutic Ultrasound
Description: Therapeutic Ultrasound to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Myofascial Release Technique
Description: Myofascial Release Technique to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
Study: NCT06550362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sulfate
Description: Oral iron administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sulfate
Description: Oral iron administration
Study: NCT05657964

Intervention type: DEVICE
Intervention: Gokhale sensor
Description: Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
Study: NCT06145880

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence tool for transthoracic echocardiography
Description: Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence tool for transthoracic echocardiography
Description: Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence tool for transthoracic echocardiography
Description: Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence tool for transthoracic echocardiography
Description: Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence tool for transthoracic echocardiography
Description: Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.
Study: NCT06415279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Winlevi (clascoterone) 1% cream
Description: Twice daily (BID) dosing
Study: NCT05167396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retinaute (BioSerenity)
Description: Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retinaute (BioSerenity)
Description: Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retinaute (BioSerenity)
Description: Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Headset 64 electrodes (BioSemi)
Description: EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Headset 64 electrodes (BioSemi)
Description: EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Headset 64 electrodes (BioSemi)
Description: EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MonPackOne (Metrovision)
Description: Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective
Study: NCT04764825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age.
Study: NCT04846920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: 40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: 40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: 40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: 40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.
Study: NCT05727865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online CBT following cardiac surgery
Description: It will include psychoeducation, behavioral activation to address post-operative fatigue and depression, interoceptive exposure to reduce fear of cardiac-related symptoms and in-vivo exposure to reduce avoided situations, and activities to enhance physical activity and wellbeing. Labeling (i.e., describing post-operative and/or cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure and pain management
Study: NCT04369274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with the automated BVM compressor
Description: Mechanical ventilation is accomplished with a device that mechanically squeezes a manual bag valve instead of by hand. The rate and volume of compression are adjustable, and the device has appropriate alarms and safety features.
Study: NCT05845671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab 1050mg
Description: Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab 1400mg
Description: Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab (to be determined)
Description: Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab (to be determined)
Description: Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In
Study: NCT06145451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Success Network
Description: The Family Success Network (FSN) is a community-based maltreatment prevention program that is being piloted to serve caregivers of children aged between 0-18 in the Trumbull, Mahoning, and Columbiana Counties in Ohio. FSN is a comprehensive multi-tier program providing information and referrals to community resources at Tier I (i.e., the initial contact stage), caregiver education, and financial literacy program along with concrete support at Tier II (i.e., enrollment in family coaching services in FSN), and a life skills program and monthly home visits for families with more intensive needs at tier III (most intensive level of FSN services).
Study: NCT06123897

Intervention type: OTHER
Intervention: Regular follow-up assessments without intervention.
Description: Participants will undergo follow-up for a minimum of one year, with regular clinical data collection at baseline, half a month, 1st month, 3rd months, 6th months, 9th months and 12th months. Baseline assessments will include demographic information, medical history, and previous medication use. For participants on antipsychotics at baseline, the Simpson-Angus Scale for extrapyramidal symptoms(SAS) will also be administered. At baseline and each follow-up, data on current medication, physical examination, anthropometry, ECG, EEG, psychiatric scales (PANSS, CGI, GAF, PSP, SAS, TESS, MMAS-8), the MATRICS Consensus Cognitive Battery, and laboratory tests (blood routine, liver and renal function, lipids, fasting glucose, fasting insulin, HbA1c) will be obtained, alongside fMRI, eye movement, and fNIRS measures. Blood samples will be collected and stored for mechanistic investigations.

Intervention type: OTHER
Intervention: Cross-sectional assessment
Description: Volunteers will undergo assessments, including SCID scale, SCL-90, Chinese Perceived Stress Scale(CPSS), the Measurement and Treatment Research to Improve Cognition in Schizophrenia(MATRICS) Consensus Cognitive Battery, blood test(blood routine, liver function, renal function, blood lipids, fasting blood glucose, fasting serum insulin, fasting blood glycosylated hemoglobin), as well as functional MRI, eye movement, functional near-infrared spectroscope and electroencephalogram. Blood samples for exploring difference between patients and healthy people will be collected and stored.
Study: NCT06531343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LDCT scan and simultaneous [18F]FDG PET/CT on new-generation long axial field of view scanner
Description: 18F\]FDG will be injected intravenously, and PET/CT images will be acquired after 60 minutes (± 10 minutes). PET/CT images will be first analysed with the lung window to detect any findings suggestive of a lung tumour.~Whole-body PET/CT images will be then analysed to detect any incidental finding in the chest as well as other anatomical areas included in the field of view. PET/CT images will be considered positive if there is at least one non-calcified lung nodule or any suspicious finding on CT scan characterised by focal \[18F\]FDG uptake deviating from physiological distribution or above physiological background activity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LDTC only
Description: The LDCT scan will be performed in single deep inspiratory breath hold. No intravenous contrast will be administered.
Study: NCT05477069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovative medical device for sampling small intestine content
Description: Ingestion of the medical device by the volunteer
Study: NCT05560802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHOs Labour care guide
Description: Guidelines for monitoring labor progress, the WHOs LCG
Study: NCT06467305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.
Study: NCT05848635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride
Description: Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation
Study: NCT05068440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: administered orally as capsules
Study: NCT06256497

Intervention type: DEVICE
Intervention: Duodenal Mucosal Resurfacing (DMR)
Description: The Revita System is a hydrothermal ablation system, (CE) certified, intended to impart insulin-sensitizing properties to the body via ablation \& rejuvenation of the duodenal mucosa. As an adjunct to diet and exercise, Revita is intended to 1. improve glycemic control in patients with T2D who have preserved pancreatic beta cell function and whose diabetes is inadequately controlled despite oral and/or injectable glucose lowering medications and/or long-acting insulin therapy, 2. Reduce liver fat in patients with T2D and Non-Alcoholic Fatty Liver Disease (NAFLD). The single use Revita Catheter and Line Set are provided sterile and are not implantable or reusable. These disposables are used with the Revita Console an electromechanical device that controls the ablation cycle and submucosal expansion. The Revita System is used in a suitably equipped endoscopy suite. The Catheter contacts the patient's digestive tract for approximately 45-60 minutes.
Study: NCT06534216

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal ultrasound
Description: This study employs intestinal ultrasound (IUS) to assess disease activity in Inflammatory Bowel Disease (IBD) patients. Ultrasound parameters include bowel wall thickness measurement, evaluation of vascularization via color Doppler, assessment of wall stratification, and identification of mesentery features and complications (e.g., strictures, fistulas, abscesses). For ulcerative colitis, disease activity is gauged using the Milan Ultrasound Criteria (MUC), where a score \>6.3 indicates active disease based on bowel wall thickness and vascularization. In Crohn's disease, the Bowel Ultrasound Score (BUSS) and International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) assess bowel wall thickness, vascularization, stratification, and inflammatory fat, with scores \>3.52 (BUSS) and \>48.7 (IBUS-SAS) indicating active disease. IUS evaluations occur at baseline, 2-6 weeks, 12 weeks, and 6-12 months to track disease progression and treatment response.
Study: NCT05843695

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iTCBT-G
Description: Group format over 2 days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard care
Study: NCT06467305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech
Study: NCT05867511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPAL App
Description: The intervention will have a duration of eight weeks. It is theory-based, will be delivered to participants' smartphones via the study app (except components 5 and 6), and comprises the following components:~1. Theory-based individualized feedback.~2. Self-generated motivational messages.~3. Motivation for habit formation through push messages.~4. Motivational images and videos that participants handed in or selected will be sent to them through the app.~5. Study-specific social media groups. Participants will be offered the option to participate in study-specific social media groups.~6. Posting motivational stories. A story of a person, who successfully changed his or her lifestyle to be more physically active and/or less sedentary, will be posted once a week in the study-specific social media groups.
Study: NCT05463224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib group
Description: Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
Study: NCT05870176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Referral
Description: The enhanced referral uses an electronic referral and patient decision aid to provide choices to 3 different physical activity programs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Referral
Description: The standard referral period will serve as the usual care comparator. Patients will receive a paper referral and Fitbit monitor.
Study: NCT06411548

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InsuLearn
Description: InsuLearn is an artificial intelligence (AI)-algorithm that analyses collected participants data: CGM, insulin, and meal categories to learn the optimal insulin dose. InsuLearn will run offline in a study laptop to generate the optimal insulin dose for each meal category. The algorithm will generate an ambulatory glucose profile (AGP) report with new settings for the InPen™ meal estimation bolus calculator. The study physician will review the report and the algorithm recommendations. The study physician can accept or modify the algorithm recommendations as per his judgment. The new settings will be used during the intervention admission.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InsuLearn
Description: InsuLearn is an artificial intelligence (AI)-algorithm that analyses collected participants data: CGM, insulin, and meal categories to learn the optimal insulin dose. InsuLearn will run offline in a study laptop to generate the optimal insulin dose for each meal category. The algorithm will generate an ambulatory glucose profile (AGP) report with new settings for the InPen™ meal estimation bolus calculator. The study physician will review the report and the algorithm recommendations. The study physician can accept or modify the algorithm recommendations as per his judgment. The new settings will be used during the intervention admission.
Study: NCT06117267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatase Spine Surgery Navigation System
Description: Collect images with the probe touching the target position before screw implantation
Study: NCT06653257

Intervention type: OTHER
Intervention: Active surveillance
Description: a non-operative management strategy aimed at avoiding unnecessary surgery in patients with thyroid nodules with a cytopathological diagnosis of Bethesda IV-VI, who do not present clinical or imaging characteristics suggesting malignancy and/or aggressiveness.